{"product_id":"fbrx-vrio-analysis","title":"Forte Biosciences, Inc. (FBRX): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the secrets to Forte Biosciences, Inc. (FBRX)'s market staying power starts here: this concise VRIO analysis cuts straight to the chase, revealing precisely which of their assets are truly Valuable, Rare, Inimitable, and Organized for lasting competitive advantage. Don't just guess their strategy - read the distilled verdict below to see if Forte Biosciences, Inc. (FBRX) is built to win.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eForte Biosciences, Inc. (FBRX) - VRIO Analysis: Proprietary Molecule FB102 (Anti-CD122 Antibody)\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at Forte Biosciences, Inc. (FBRX) and trying to figure out if their lead asset, FB102, is a real game-changer or just another promising molecule in a crowded field. Honestly, the data coming out of their late 2025 trials suggests this anti-CD122 antibody has the legs to be a significant asset, but the real test is still ahead in 2026.\u003c\/p\u003e\n\n\u003cp\u003eThe company is definitely putting all its chips on this one. For the nine months ended September 30, 2025, Research and development expenses hit \u003cstrong\u003e$36.5 million\u003c\/strong\u003e, a big jump from $16.0 million the year prior, mainly driven by advancing FB102 through its celiac disease Phase 2 trial and the ongoing Phase 1b studies in vitiligo and alopecia areata. That level of focused spend, supported by a cash position of \u003cstrong\u003e$93.4 million\u003c\/strong\u003e as of that same date, shows their organizational commitment to this single lead candidate.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on what makes FB102 potentially special, based on what we know right now:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIt targets CD122, which is the Interleukin-2 receptor beta chain.\u003c\/li\u003e\n\u003cli\u003ePhase 1b Celiac Disease (CeD) data from June 2025 showed a statistically significant benefit on the VCIEL endpoint (p=0.0099).\u003c\/li\u003e\n\u003cli\u003eIt caused a 95% decline in NK cells following dosing in the CeD study.\u003c\/li\u003e\n\u003cli\u003eTopline data for Vitiligo is penciled in for the first half of 2026 (1H26), with Alopecia Areata data expected later that year.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eWhat this estimate hides is the execution risk between now and those 2026 readouts; if the Phase 2 CeD data disappoints, the advantage evaporates fast.\u003c\/p\u003e\n\n\u003cp\u003eWe can map out the VRIO assessment for FB102 below. Remember, this is a snapshot based on the molecule's current profile and the company’s structure around it.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Dimension\u003c\/th\u003e\n\u003cth\u003eAssessment for FB102 (Anti-CD122 Antibody)\u003c\/th\u003e\n\u003cth\u003eSupporting Detail\/Data\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eValue (V)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eOffers potential blockbuster status across multiple high-unmet-need autoimmune indications: Celiac Disease (CeD), Vitiligo, and Alopecia Areata.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRarity (R)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eA novel, proprietary molecule with positive Phase 1b data in CeD is rare, especially one specifically targeting CD122.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eImitability (I)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eHigh Cost\/Difficulty\u003c\/td\u003e\n\u003ctd\u003eThe specific structure and mechanism of action are protected by patents, making direct imitation a slow and expensive process for competitors.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eOrganization (O)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eThe entire R\u0026amp;D spend of \u003cstrong\u003e$36.5 million\u003c\/strong\u003e for the nine months ended September 30, 2025, is channeled into advancing this single lead candidate.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSustained (Conditional)\u003c\/td\u003e\n\u003ctd\u003eSustained advantage is contingent on Phase 2 data in 2026 validating the mechanism observed in Phase 1b.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe core of the current advantage rests on the mechanism. The fact that FB102 is an IL-2R$\\beta$ inhibitor, which led to a decline in pro-inflammatory TCR $\\gamma\\delta$ cells (p=0.0007) and NK cells (\u003cstrong\u003e95%\u003c\/strong\u003e decline) in the CeD trial, suggests a potent, differentiated biological effect. This isn't just about having a drug; it's about having a drug that hits a specific, hard-to-reach pathway in autoimmunity.\u003c\/p\u003e\n\n\u003cp\u003eTo maintain this, Forte Biosciences needs to execute flawlessly on its near-term milestones. If onboarding takes 14+ days longer than expected for the Phase 2 CeD trial, the timeline for that crucial 2026 readout slips, and the perceived advantage diminishes. The company needs to show they are organized enough to handle the expanded US enrollment in the CeD trial effectively.\u003c\/p\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eForte Biosciences, Inc. (FBRX) - VRIO Analysis: Positive Phase 1b Celiac Disease Data\n\u003c\/h2\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eProvides crucial, early proof-of-concept that FB102 can modulate the immune response in a human disease setting, de-risking the asset significantly.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eEndpoint\u003c\/td\u003e\n\u003ctd\u003eFB102 Result\u003c\/td\u003e\n\u003ctd\u003ePlacebo Result\u003c\/td\u003e\n\u003ctd\u003eP-Value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eComposite Histological VCIEL Endpoint Change from Baseline\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.079\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-1.849\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.0099\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChange in CD3-positive T cells (IELs) from Baseline\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e-1.5\u003c\/strong\u003e (Decrease)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e13.3\u003c\/strong\u003e (Increase)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.0035\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVh:Cd Ratio Change from Baseline\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-0.046\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-0.173\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e73%\u003c\/strong\u003e Improvement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGluten Challenge-Induced GI Symptoms (Events\/Subject)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4.0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6.9\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e42%\u003c\/strong\u003e Benefit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial Enrollment (Total Subjects)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e32\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubjects Receiving FB102\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e24\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eModerate. Many companies have Phase 1 data, but positive, human proof-of-concept in a difficult indication like CeD is not common.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eTemporary. Competitors can replicate the study design, but they cannot replicate the actual data Forte Biosciences already possesses.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eYes. The company is actively using this data to expand the Phase 2 CeD trial into US sites.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePhase 2 Celiac Disease (CeD) trial topline results expected in \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eUS IND approved for Phase 2 CeD trial expansion.\u003c\/li\u003e\n\u003cli\u003ePhase 1b Vitiligo trial topline data expected in \u003cstrong\u003e1H26\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents as of Q3 2025: \u003cstrong\u003e\\$93.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePublic offering of \u003cstrong\u003e\\$75 million\u003c\/strong\u003e closed on June 24, 2025, priced at \u003cstrong\u003e\\$12.00\u003c\/strong\u003e per share.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses for the nine months ended September 30, 2025: \u003cstrong\u003e\\$36.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet loss per share for the three months ended September 30, 2025: \u003cstrong\u003e\\$(0.99)\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eTemporary, as the market will price in the next data point, but it’s a critical near-term advantage.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMarket capitalization at time of data release: \u003cstrong\u003e\\$96.51 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAnalyst price targets ranged from \u003cstrong\u003e\\$28\u003c\/strong\u003e to \u003cstrong\u003e\\$61\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eStock return over the past year (at data release): \u003cstrong\u003e20%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCurrent Ratio (at data release): \u003cstrong\u003e5.22\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eForte Biosciences, Inc. (FBRX) - VRIO Analysis: Multi-Indication Clinical Breadth\n\u003c\/h2\u003e\n\u003cp\u003eThe analysis focuses on the multi-indication strategy centered around the lead product candidate, \u003cstrong\u003eFB102\u003c\/strong\u003e, an anti-CD122 monoclonal antibody therapeutic candidate.\u003c\/p\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eDiversifies risk away from a single indication; success in one (like CeD) can rapidly unlock value in the others (Vitiligo, Alopecia Areata). The potential market opportunities across these indications are described as representing \u003cstrong\u003emulti-billion dollar\u003c\/strong\u003e potential market opportunities. The FB102-101 Phase 1b celiac disease study enrolled \u003cstrong\u003e32 subjects\u003c\/strong\u003e, randomized \u003cstrong\u003e3:1\u003c\/strong\u003e (\u003cstrong\u003e24\u003c\/strong\u003e on FB102 and \u003cstrong\u003e8\u003c\/strong\u003e on placebo).\u003c\/p\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eModerate. Having \u003cstrong\u003ethree\u003c\/strong\u003e active or initiating clinical trials for one molecule (\u003cstrong\u003eFB102\u003c\/strong\u003e) is a sign of broad applicability for a company of this size. The indications being pursued concurrently are Celiac Disease (CeD), Vitiligo, and Alopecia Areata.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eHigh. Competitors would need to run separate, expensive trials to prove efficacy in these other indications. The company's Research and development expenses for the nine months ended September 30, 2025, were \u003cstrong\u003e$36.5 million\u003c\/strong\u003e, reflecting costs associated with advancing FB102 through the Phase 2 CeD trial and Phase 1b trials for Vitiligo and Alopecia Areata.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eYes. The team is managing \u003cstrong\u003ethree\u003c\/strong\u003e separate clinical trials concurrently, showing organizational focus on platform expansion. Key data readouts are anticipated in \u003cstrong\u003e2026\u003c\/strong\u003e for all three indications.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eResearch and development expenses for the three months ended September 30, 2025, were \u003cstrong\u003e$15.2 million\u003c\/strong\u003e, primarily due to increases in clinical and manufacturing expenses related to the Phase 2 CeD trial and Phase 1b trials for Vitiligo and Alopecia Areata.\u003c\/li\u003e\n\u003cli\u003eForte ended the third quarter of 2025 with \u003cstrong\u003e$93.4 million\u003c\/strong\u003e in cash and cash equivalents.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe current clinical program status is summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndication\u003c\/td\u003e\n\u003ctd\u003eMolecule\u003c\/td\u003e\n\u003ctd\u003eCurrent Phase Status\u003c\/td\u003e\n\u003ctd\u003eExpected Topline Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCeliac Disease (CeD)\u003c\/td\u003e\n\u003ctd\u003eFB102\u003c\/td\u003e\n\u003ctd\u003ePhase 2 (Enrolling, US sites expanded)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVitiligo\u003c\/td\u003e\n\u003ctd\u003eFB102\u003c\/td\u003e\n\u003ctd\u003ePhase 1b (Ongoing)\u003c\/td\u003e\n\u003ctd\u003e1H\u003cstrong\u003e26\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlopecia Areata\u003c\/td\u003e\n\u003ctd\u003eFB102\u003c\/td\u003e\n\u003ctd\u003ePhase 1b (Enrolling patients)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eSustained, as long as the pipeline remains broad and data positive across the indications, validating the platform approach of \u003cstrong\u003eFB102\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eForte Biosciences, Inc. (FBRX) - VRIO Analysis: Strong Cash Position for Development\n\u003c\/h2\u003e\n\u003ch\u003eStrong Cash Position for Development\u003c\/h\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The \u003cstrong\u003e$93.4 million\u003c\/strong\u003e in cash and cash equivalents as of September 30, 2025, funds operations and clinical milestones without immediate dilution pressure.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. For a clinical-stage company, this level of cash, especially after the June 2025 offering, provides a solid runway.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. Competitors must raise capital in the market, which is subject to investor sentiment.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. The company has demonstrated an ability to access capital, closing an over-subscribed private placement in late 2024 and a public offering in June 2025.\u003c\/p\u003e\n\u003cp\u003eThe robust balance sheet as of September 29, 2025, shows total assets of \u003cstrong\u003e$97.1M\u003c\/strong\u003e against total liabilities of \u003cstrong\u003e$13.0M\u003c\/strong\u003e, with total debt at \u003cstrong\u003e$0.0\u003c\/strong\u003e. The net cash position is \u003cstrong\u003e$93.41 million\u003c\/strong\u003e, equating to \u003cstrong\u003e$5.24\u003c\/strong\u003e per share.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancing Event\u003c\/th\u003e\n\u003cth\u003eDate\u003c\/th\u003e\n\u003cth\u003eGross Proceeds (USD)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivate Placement\u003c\/td\u003e\n\u003ctd\u003eLate 2024 (Announced Nov 20, 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$53 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic Offering\u003c\/td\u003e\n\u003ctd\u003eJune 2025\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$75 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eOrganizational capacity to secure funding is evidenced by recent capital raises:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe late 2024 private placement was \u003cstrong\u003eoversubscribed\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe June 2025 public offering was priced at \u003cstrong\u003e$12.00\u003c\/strong\u003e per share.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe cash position supports ongoing development, despite an accelerated burn rate, with a Q3 2025 net loss of \u003cstrong\u003e$17.7M\u003c\/strong\u003e and R\u0026amp;D expenses of \u003cstrong\u003e$15.2M\u003c\/strong\u003e. The forecast cash runway is estimated at \u003cstrong\u003e1.6 years\u003c\/strong\u003e based on historical free cash flow reduction rates of \u003cstrong\u003e25.9%\u003c\/strong\u003e per year.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as cash burns, but it buys time until the next inflection point.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eForte Biosciences, Inc. (FBRX) - VRIO Analysis: Experienced, Founder-Led Management\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The team, led by CEO Paul Wagner, PhD, who founded Forte, brings deep, relevant experience in biotech R\u0026amp;D and strategy.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While many biotechs have experienced leaders, this specific combination of R\u0026amp;D depth (like Dr. Doberstein) and financial acumen (like Mr. Gryska) is unique to Forte Biosciences, Inc.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. You can hire away individuals, but replicating the established internal culture and shared history is very tough.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. The team is clearly aligned on the FB102 strategy, evidenced by the rapid initiation of three trials.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as long as the core leadership remains intact.\u003c\/p\u003e\n\u003cp\u003eKey Management and Pipeline Metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eContext\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCEO Tenure (Appointed Jan 2018)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7.92 years\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePaul A. Wagner, Ph.D.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCEO Total Compensation (FY2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1,674,458\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePaul A. Wagner, Ph.D.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCEO Base Salary (FY2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$644,280\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePaul A. Wagner, Ph.D.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCEO Stock Award Value (FY2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$643,610\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePaul A. Wagner, Ph.D.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCEO Direct Ownership Percentage\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.46%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePaul A. Wagner, Ph.D.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFB102 CeD Phase 1b Enrollment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e32 subjects\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e24 on FB102\u003c\/strong\u003e, \u003cstrong\u003e8 on placebo\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFB102 CeD GI Symptom Benefit\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e42%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFB102 treated subjects (4.0 events\/subject) vs. placebo (6.9 events\/subject)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFB102 CeD IEL Density Change\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e-1.5\u003c\/strong\u003e vs. \u003cstrong\u003e+13.3\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFB102 treated vs. placebo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected FB102 Readouts in 2026\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCeD Phase 2, Vitiligo Phase 1b, Alopecia Areata Phase 1b\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eDr. Paul Wagner's background includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eChief Executive Officer of Forte Biosciences, Inc. since \u003cstrong\u003e2018\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eFormer Chief Financial Officer of Pfenex Inc. (2014 to 2017).\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eDirector and Portfolio Manager\/Sr. Equity Analyst with Allianz Global Investors (2006 to 2014), responsible for biotechnology and pharmaceutical investments.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eReceived a Ph. D. in Chemistry from the California Institute of Technology in \u003cstrong\u003e1999\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eDr. Stephen Doberstein's relevant experience includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eMost recently served as Chief R\u0026amp;D Officer at Nektar Therapeutics.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eHeld VP, Research positions at Xencor, FivePrime Therapeutics, and Xoma.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinancial Data Related to R\u0026amp;D Advancement:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses were \u003cstrong\u003e$8.6 million\u003c\/strong\u003e for the three months ended June 30, 2025.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses were \u003cstrong\u003e$21.3 million\u003c\/strong\u003e for the six months ended June 30, 2025.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eGeneral and administrative expenses were \u003cstrong\u003e$3.2 million\u003c\/strong\u003e for the three months ended September 30, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eForte Biosciences, Inc. (FBRX) - VRIO Analysis: Clinical Research Footprint (NA \u0026amp; Europe)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Allows for faster patient recruitment by accessing diverse patient populations and clinical sites across two major regulatory zones.\u003c\/p\u003e\n\u003cp\u003eThe clinical footprint supports the advancement of FB102, with the Phase 2 Celiac Disease (CeD) trial currently enrolling patients, including expansion to US sites following IND approval. The operational scale is reflected in the financial investment:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 1b CeD Trial Enrollment\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e32\u003c\/strong\u003e subjects (\u003cstrong\u003e24\u003c\/strong\u003e FB102, \u003cstrong\u003e8\u003c\/strong\u003e placebo)\u003c\/td\u003e\n\u003ctd\u003eFB102-101 Study\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2 CeD Trial Status\u003c\/td\u003e\n\u003ctd\u003eEnrolling, US IND open\u003c\/td\u003e\n\u003ctd\u003eAs of Q3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2 CeD Data Readout Expectation\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFB102 Phase 2 Celiac Disease\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (Clinical\/Mfg Focus)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$9.7 million\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 vs Q3 2024 (related to Phase 2 CeD \u0026amp; Phase 1b trials)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (Clinical\/Mfg Focus)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$21.6 million\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003ctd\u003eNine Months Ended 9\/30\/2025 vs 9\/30\/2024 (related to Phase 2 CeD \u0026amp; Phase 1b trials)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$93.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low. Most clinical-stage firms operate internationally, but it’s a necessary operational capability.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. Competitors can establish sites, though it takes time and contracts.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. They are actively enrolling in US sites for the Phase 2 trial.\u003c\/p\u003e\n\u003cp\u003eThe company's ability to execute multi-regional trials is supported by its financial structure, enabling continued clinical progression:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEnrolment in the FB102 phase 2 celiac disease (CeD) clinical trial has expanded to US sites.\u003c\/li\u003e\n\u003cli\u003eThe company reported $93.4 million in cash and cash equivalents as of September 30, 2025.\u003c\/li\u003e\n\u003cli\u003eAs of September 30, 2025, there were approximately 12.5 million shares of common stock outstanding.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e None on its own, but it enables the advantage of the pipeline.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eForte Biosciences, Inc. (FBRX) - VRIO Analysis: Proprietary Platform for Autoimmune\/Skin Barrier\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The underlying technology that produced FB102 suggests potential for future, follow-on product candidates beyond the current pipeline.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While the specific platform isn't detailed, the focus on topical live biotherapeutics\/skin barrier is a specialized niche.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Replicating the discovery engine that generates these proprietary molecules takes years of focused research investment.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. The company is exploring pipeline opportunities in rare genetic skin conditions, showing platform application.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as it feeds the long-term pipeline.\u003c\/p\u003e\n\u003cp\u003ePlatform Application and Financial Context:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003ctd\u003eDate\/Period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead Candidate\u003c\/td\u003e\n\u003ctd\u003eFB102 (Anti-CD122 Monoclonal Antibody)\u003c\/td\u003e\n\u003ctd\u003eOngoing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$93.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$150M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNovember 7, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e16.00\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Reported\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$15.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e3 Months Ended Sep 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss Per Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$(3.26)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e9 Months Ended Sep 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003ePipeline Indications for FB102:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCeliac Disease (CeD) - Phase \u003cstrong\u003e2\u003c\/strong\u003e trial initiated; Topline expected in \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eVitiligo - Phase \u003cstrong\u003e1b\u003c\/strong\u003e study ongoing; Topline expected in \u003cstrong\u003e1H26\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAlopecia Areata - Phase \u003cstrong\u003e1b\u003c\/strong\u003e trial initiating in \u003cstrong\u003e2H25\u003c\/strong\u003e; Topline expected in \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eType 1 Diabetes (T1D) - Potential indication.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIntellectual Property Context:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eForte Biosciences challenged a University of Massachusetts patent related to IL-15 or IL-15 receptor inhibitors for vitiligo treatment.\u003c\/li\u003e\n\u003cli\u003ePreviously reported having seven U.S. patents covering composition and method of use for technology focused on inflammatory skin conditions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eForte Biosciences, Inc. (FBRX) - VRIO Analysis: High Institutional Ownership\n\u003c\/h2\u003e\n\u003cp\u003e\nValue: A high percentage of ownership by institutions (77.63% as of late 2025) suggests strong conviction from professional money managers.\n\u003c\/p\u003e\n\u003cp\u003e\nThe total number of institutional owners reporting positions is 76 funds or institutions. These institutions hold a total of 11,680,994 shares. The share price as of November 28, 2025, was $18.56 \/ share.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional Holder\u003c\/td\u003e\n\u003ctd\u003eOwnership Percentage\u003c\/td\u003e\n\u003ctd\u003eShares Held (Approx.)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFred Alger Management, LLC\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e13.06%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e1,636K\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFederated Hermes Inc.\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e13.05%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e1,635K\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJanus Henderson Group PLC\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11.21%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e1,404K\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrbimed Advisors LLC\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e9.56%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e1,197K\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTybourne Capital Management\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6.28%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e787K\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nRarity: Moderate. High institutional ownership is common for listed biotechs, but the quality of the holders matters.\n\u003c\/p\u003e\n\u003cp\u003e\nThe ownership structure includes:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInstitutional Shareholders: \u003cstrong\u003e77.63%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eForte Biosciences Insiders: \u003cstrong\u003e49.14%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eRetail Investors: \u003cstrong\u003e0.00%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\nThe CEO, Paul A. Wagner, directly holds 0.7% of total shares outstanding.\n\u003c\/p\u003e\n\u003cp\u003e\nImitability: Low. You can’t force institutions to buy your stock; it requires market validation.\n\u003c\/p\u003e\n\u003cp\u003e\nOrganization: Yes. This ownership base provides stability and access to future capital markets if needed.\n\u003c\/p\u003e\n\u003cp\u003e\nCompetitive Advantage: Temporary, as institutional sentiment can shift quickly on negative data.\n\u003c\/p\u003e\n\u003cp\u003e\nRecent institutional activity shows changes:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal shares owned by institutions increased in the last three months by 10.73%.\u003c\/li\u003e\n\u003cli\u003eThe number of reporting funds increased by 46.15% in the last quarter to 76 owners.\u003c\/li\u003e\n\u003cli\u003eThe put\/call ratio of FBRX is 0.08, indicating a bullish outlook.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eForte Biosciences, Inc. (FBRX) - VRIO Analysis: Low Short Interest\n\u003c\/h2\u003e\n\u003cp\u003eThe analysis below incorporates the latest available statistical data for Forte Biosciences, Inc. (FBRX) to assess the Value, Rarity, Inimitability, and Organization of its current low short interest position.\u003c\/p\u003e\n\n\u003ch\u003eVRIO Framework Application: Low Short Interest\u003c\/h\u003e\n\u003cul\u003e\n    \u003cli\u003e\n        \u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e A low short interest of \u003cstrong\u003e2.40%\u003c\/strong\u003e of outstanding shares, or \u003cstrong\u003e3.63%\u003c\/strong\u003e of the public float, indicates that a significant portion of the market is not betting against the stock.\u003c\/p\u003e\n    \u003c\/li\u003e\n    \u003cli\u003e\n        \u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Temporary. This metric fluctuates, with the latest short interest being \u003cstrong\u003e427,816\u003c\/strong\u003e shares sold short as of November 14, 2025, which is a \u003cstrong\u003e-9.54%\u003c\/strong\u003e decrease since the prior report.\u003c\/p\u003e\n    \u003c\/li\u003e\n    \u003cli\u003e\n        \u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. It reflects current market positioning, not a controllable internal asset.\u003c\/p\u003e\n    \u003c\/li\u003e\n    \u003cli\u003e\n        \u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. It reduces the risk of a sharp, sentiment-driven sell-off triggered by short-sellers covering, especially with a short interest ratio (days to cover) of approximately \u003cstrong\u003e6.8\u003c\/strong\u003e.\u003c\/p\u003e\n    \u003c\/li\u003e\n    \u003cli\u003e\n        \u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, but it provides a cleaner trading environment for the next catalyst.\u003c\/p\u003e\n    \u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eFinancial Sensitivity Analysis: Cash Runway Based on R\u0026amp;D Burn Rate\u003c\/h\u003e\n\u003cp\u003eThis sensitivity analysis projects the cash runway based on the latest reported cash balance and the specified nine-month R\u0026amp;D burn rate of \u003cstrong\u003e$36.5 million\u003c\/strong\u003e. The latest reported cash and cash equivalents balance was \u003cstrong\u003e$106 million\u003c\/strong\u003e as of June 2025.\u003c\/p\u003e\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eScenario\u003c\/th\u003e\n        \u003cth\u003eR\u0026amp;D Burn Rate (9 Months)\u003c\/th\u003e\n        \u003cth\u003eImplied Monthly R\u0026amp;D Burn\u003c\/th\u003e\n        \u003cth\u003eCash Balance (Latest Reported)\u003c\/th\u003e\n        \u003cth\u003eProjected Cash Runway (Months)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e\u003cstrong\u003eBase Case (Prompt Driven)\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e$36.5 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e$4.056 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e$106 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e26.13\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eAccelerated Burn\u003c\/td\u003e\n        \u003ctd\u003e$45.0 million\u003c\/td\u003e\n        \u003ctd\u003e$5.000 million\u003c\/td\u003e\n        \u003ctd\u003e$106 million\u003c\/td\u003e\n        \u003ctd\u003e21.20\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eReduced Burn\u003c\/td\u003e\n        \u003ctd\u003e$30.0 million\u003c\/td\u003e\n        \u003ctd\u003e$3.333 million\u003c\/td\u003e\n        \u003ctd\u003e$106 million\u003c\/td\u003e\n        \u003ctd\u003e31.80\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e12-Month Actual Burn (Context)\u003c\/td\u003e\n        \u003ctd\u003e$44.43 million (12 Months)\u003c\/td\u003e\n        \u003ctd\u003e$3.703 million\u003c\/td\u003e\n        \u003ctd\u003e$106 million\u003c\/td\u003e\n        \u003ctd\u003e28.62\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe 12-month operating cash flow burn was reported as \u003cstrong\u003e-$44.43 million\u003c\/strong\u003e, which implies a runway of approximately \u003cstrong\u003e2.7 years\u003c\/strong\u003e based on the \u003cstrong\u003e$106 million\u003c\/strong\u003e cash position as of June 2025.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516163317909,"sku":"fbrx-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/fbrx-vrio-analysis.png?v=1740175244","url":"https:\/\/dcf-model.com\/fr\/products\/fbrx-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}